Exploring the relationship between the immune system and gastrointestinal cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how the characteristics of the tumor microenvironment and the immune system affect the survival of patients with gastrointestinal cancers, particularly colorectal and pancreaticobiliary cancers. It includes a retrospective cohort of 150 patients diagnosed between 1998 and 2020 and a prospective cohort of 3000 patients diagnosed between 2020 and 2030, with a follow-up period of 10 years. The study will analyze molecular subgroups through DNA and RNA analysis, as well as assess the impact of host factors such as microbiota and metabolism on treatment response and tolerance. All treatment decisions will be made by the investigator physician based on established guidelines.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Carcinoma of colorectal, pancreatic, biliary tract or gastro-oesophageal, or neuroendocrine digestive tumors with cytologically or histologically proven, regardless of the stage;
* Diagnosis between 1998 and 2030;
* Be \>/= 18 years;
* Have obtained signed informed consent (exemption for dead patients);
* Affiliated to the French social security - welfare system in France (CMU included).

Exclusion Criteria:

* Patient under tutoraship or curatorship;
* Foreign patient under AME schema, a medical help from the state in France;
* Pregnant or breastfeeding women (for prospective study);
* Any clinical, psychological or social reason which should influence patient compliance with protocol, according to investigator;
* Patient refusal.

Where it's running

• Digestive Surgery Department, Ambroise Paré Hospital, APHP
  Boulogne-Billancourt, France Recruiting

Study contacts

• Principal investigator: Frédérique PESCHAUD, MD, PhD — Digestive Surgery Department, Ambroise Paré Hospital, APHP
• Study coordinator: Frédérique PESCHAUD, MD, PhD
• Email: frederique.peschaud@aphp.fr
• Phone: +33 1 49 09 53 35

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preoperative Muscle Health and Postoperative Outcomes in Older Adults with GI Cancer

  This study looks at whether having sarcopenia before surgery affects recovery and complications after GI cancer surgery in people 60 and older.

  Recruiting Van Training and Research Hospital · Van, Van · NCT07817758

• Velzatinib for advanced GIST after multiple prior TKIs

  This study tests velzatinib to see if it can shrink or slow tumors in people with metastatic or unresectable GIST who have progressed on or could not tolerate standard therapies.

  Recruiting at 3 sites Phase 2 GlaxoSmithKline · Fukuoka and 2 other locations · NCT07689201

• Romiplostim N01 plus ATRA for persistent low platelets after cancer remission

  This study tests whether adding all-trans retinoic acid to Romiplostim N01 helps people who still have low platelets after GI/digestive system cancer remission reach safer platelet levels.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586813

• Fecal transplant for chemotherapy and targeted-therapy gut side effects in advanced gastrointestinal cancer

  This trial will try oral fecal microbiota transplants (FMT) to see if they reduce chemotherapy or targeted-therapy–related gut symptoms in adults with advanced gastrointestinal cancers.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Zhejiang, Hangzhou · NCT07319364

• PF-08634404 plus chemotherapy for adults with metastatic colorectal cancer

  This trial will test whether adding a new drug called PF-08634404 to standard chemotherapy helps adults whose colorectal cancer has spread.

  Recruiting at 343 sites Phase 3 Pfizer · Chandler, Arizona and 371 other locations · NCT07222800

• IDRX-42 versus sunitinib for adults with advanced gastrointestinal stromal tumors after imatinib

  This test compares IDRX-42 (GSK6042981) with sunitinib in adults with advanced or unresectable GIST who have already been treated with imatinib to see which controls the cancer better and is safer.

  Recruiting at 156 sites Phase 3 GlaxoSmithKline · Phoenix, Arizona and 155 other locations · NCT07218926

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.